Hong Kong Biotech Sector Flourishes Amid China’s Biopharma Surge

Hong Kong’s biotech sector has experienced significant growth, transitioning from a mere listing venue to a hub of biotech products and derivatives. This evolution has deepened liquidity and diversified access to biotech investments. The surge in biotechnology in Hong Kong is primarily fueled by China’s expanding capacity for drug development, increased licensing activity, and supportive policy reforms. The value of biotech licensing deals is expected to double in the next 18-24 months, driven by global drug manufacturers seeking China-developed experimental medicines. This trend is accelerating the sector’s shift from research to commercialization, with Hong Kong playing a pivotal role in…